Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Activist Ed Garden lauds new Fortune Brands CEO - Bloomberg
• SanDisk (SNDK) PT Raised to $3,000 at Bernstein SocGen Group, 'We believe this is not understood by the Street'